-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $105

Benzinga·07/18/2025 14:14:51
Listen to the news
Canaccord Genuity analyst Whitney Ijem maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and raises the price target from $92 to $105.